Impressive #APEXBreast01 data showing benefit with rolditamig deuderuxtecan over first-line chemotherapy in HR+/HER2-low metastatic #BreastCancer!

📌 mPFS: 16.4 vs 5.5 months (HR 0.29)
📌 ORR more than doubled
📌 Encouraging early OS trend

#ESMO26 @OncoAlert